Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds

Molecular Pharmacology

Volumn 56, Issue 1, 1999, Pages 204-213

  Liekens, Sandra ^b,c   Leali, Daria ^a   Neyts, Johan ^b   Esnouf, Robert ^b   Rusnati, Marco ^a   Dell'era, Patrizia ^a   Maudgal, Prabhat C ^b   De Clercq, Erik ^b   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; POLY(2 ACRYLAMIDO 2 METHYL 1 PROPANESULFONIC ACID); POLYANETHOLESULFONIC ACID; POLYSTYRENESULFONIC ACID; PROTEOHEPARAN SULFATE; SULFONIC ACID DERIVATIVE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BINDING SITE; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG ACTIVITY; MITOGENESIS; MOLECULAR INTERACTION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; TARGET CELL;

EID: 0033061257     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.1.204     Document Type: Article

References (42)

1. Bastaki M, Nelli EE, Dell'Era P, Rusnati M, Molinari-Tosatti MP, Parolini S, Auerbach R, Ruco LP, Possati L and Presta M (1997) Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium: A study of aortic and microvascular endothelial cell lines. Arterioscler Thromb Vasc Biol 17:454-464.
2. Besser D, Presta M and Nagamine Y (1995) Elucidation of a signalling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth & Differ 6:1009-1017.
3. Coltrini D, Rusnati M, Zoppetti G, Oreste P, Grazioli G, Naggi A and Presta M (1994) Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. Biochem J 303:583-590.
4. Coltrini D, Rusnati M, Zoppetti G, Oreste P, Isacchi A, Caccia P, Bergonzoni L and Presta M (1993) Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. Bur J Biochem 214:51-58.
5. Edelman ER, Nugent MA and Karnovsky MJ (1993) Perivascular and intravenous administration of basic fibroblast growth factor: Vascular and solid organ deposition. Proc Natl Acad Sci USA 90:1513-1517.
6. Erikseon AE, Cousens LS and Matthews BW (1993) Refinement of the structure of human basic fibroblast growth factor at 1.6 Å resolution and analysis of presumed heparin binding sites by selenate substitution. Protein Sci 2:1274-1284.
7. Esko JD (1991) Genetic analysis of proteoglycan structure, function and metabolism. Curr Opin Cell Biol 3:805-816.
8. Esnouf RM (1997) An extensively modified version of MolScript which includes greatly enhanced colouring capabilities. J Mol Graph Model 15:132-134.
9. Faham S, Hileman RE, Fromm JR, Linhardt RJ and Rees DC (1996) Heparin structure and interactions with basic fibroblast growth factor. Science (Wash DC) 271:1116-1120.
10. Ferrin TE, Huang CC, Jarvis LE and Langridge R (1988) The Midas display system. J Mol Graph 6:13-27.
11. Firsching A, Nickel P, Mora P and Allolio B (1995) Antiproliferative and angiostatic activity of suramin analogues. Cancer Res 55:4957-4961.
12. Florkiewicz RZ, Baird A and Gonzalez AM (1991) Multiple forms of bFGF: Differential nuclear and cell surface localization. Growth Factors 4:265-275.
13. Florkiewicz RZ and Sommer A (1989) Human basic fibroblast growth factor gene encodes four polypeptides: Three initiate translation from non-AUG codons. Proc Natl Acad Sci USA 86:3978-3981.
14. Gualandris A, Urbinati C, Rusnati M, Ziche M and Presta M (1994) Interaction of high molecular weight basic fibroblast growth factor (bFGF) with endothelium: Biological activity and intracellular fate of human recombinant Mr 24,000 bFGF. J Cell Physiol 161:149-159.
15. Guimond S, Maccarana M, Olwin BB, Lindahl U and Rapraeger AC (1993) Activating and inhibitory sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2 and FGF-4. J Biol Chem 268:23906-23914.
16. Herr AB, Ornitz DM, Sasisekharan R, Venkataraman G and Waksman G (1997) Heparin-induced self-association of fibroblast growth factor-2. Evidence for two oligomerization processes. J Biol Chem 272:16382-16389.
17. Ishihara M, Tyrrell DJ, Stauber GB, Brown S, Cousens LS and Stack RJ (1993) Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem 268:4675-4683.
18. Johnson DE and Williams LT (1993) Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1-41.
19. Kraulis PJ (1991) MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24:916-950.
20. Liekens S, Neyts J, Degrève B and De Clercq E (1997) The sulfonic acid polymers PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis. Oncol Res 9:173-181.
21. Merritt EA and Murphy MEP (1994) Raster3D version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr D50:869-873.
22. Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, Chang G, Hendrickson T and Still WC (1990) MacroModel-An integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 11:440-467.
23. Moscatelli D (1992) Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors. Implications for mechanisms of bFGF release from pericellular matrix. J Biol Chem 267:25803-25809.
24. Myers C, Cooper M, Stein C, LaRocca R, McClellan MW, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J and Linehan M (1992) Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10:881-889.
25. Norrby K and Ostergaard P (1996) Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 16:8-15.
26. Pearlman DA, Case DA, Caldwell JW, Rosa WS, Cheatham TE, Ferguson DM, Seibel GL, Singh UC, Weiner PK and Kollman PA (1995) AMBER 4.1. University of California, San Francisco, CA.
27. Pepper MS (1997) Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol 17:605-619.
28. Pesenti E, Sola F, Mongelli N, Grandi M and Spreafico F (1992) Suramin prevents neovascularization and tumour growth through blocking of basic fibroblast growth factor activity. Br J Cancer 66:367-372.
29. Presta M, Moscatelli D, Joseph-Silverstein J and Rifkin DB (1986) Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis and migration. Mol Cell Biol 6:4060-4066.
30. Presta M, Tiberio L, Rusnati M, Dell'Era P and Ragnotti G (1991) Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. Cell Regul 2:719-726.
31. Ribatti D, Urbinati C, Nico B, Rusnati M, Roncali L and Presta M (1995) Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane. Dev Biol 170:39-49.
32. Richard C, Liuzzo JP and Moscatelli D (1995) Fibroblast growth factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells. J Biol Chem 270:24188-24196.
33. Rusnati M, Coltrini D, Dell'Era P, Zopetti G, Oreste P, Valsasina B and Presta M (1994) Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. Biochem Biophys Res Commun 203:450-458.
34. Saksela O, Moscatelli D, Sommer A and Rifkin DB (1988) Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107:743-751.
35. Sambrook J, Fritish EF and Maniatis T (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
36. Schlessinger J, Lax I and Lemmon M (1995) Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? Cell 83:357-360.
37. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J and Lax I (1994) Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation and cell proliferation. Cell 79:1015-1024.
38. Thompson LD, Pantoliano MW and Springer BA ( 1994) Energetic characterization of the basic fibroblast growth factor-heparin interaction: Identification of the heparin binding domain. Biochemistry 33:3831-3840.
39. Villaschi S and Nicosia RF (1993) Angiogenic role of endogenous basic fibroblast growth factor released by rat aorta after injury. Am J Pathol 143:181-190.
40. Walker A, Turnbull JE and Gallagher JT (1994) Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J Biol Chem 269:931-935.
41. Yayon A, Klagsbrun M, Esko D, Leder P and Ornitz DM (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-848
42. Zugmaier G, Lippman ME and Wellstein A (1992) Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst 84:1716-1724.